Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | PRKACG | P22612 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.33 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27188805 | 1.00 | MAPK14 (0.36) | MAPK14CYP2C9MAPK11HDAC1NAMPT | |
| SCHEMBL27188844 | 0.91 | P2RX7 (0.36) | HDAC1NAMPTROCK2SCN2ASCN10A | |
| SCHEMBL29896109 | 0.91 | P2RX7 (0.36) | HDAC1NAMPTROCK2SCN2ASCN10A | |
| SCHEMBL29896108 | 0.86 | MAPK14 (0.37) | MAPK14CYP2C9MAPK11HDAC1LMNA | |
| SCHEMBL27188809 | 0.86 | MAPK14 (0.37) | MAPK14CYP2C9MAPK11HDAC1LMNA | |
| SCHEMBL27188818 | 0.86 | ROCK2 (0.44) | CYP2C9NAMPTROCK2 | |
| SCHEMBL29896156 | 0.86 | ROCK2 (0.44) | CYP2C9NAMPTROCK2 | |
| SCHEMBL27188872 | 0.81 | NPC1 (0.37) | NAMPTHPGDROCK2 | |
| SCHEMBL29896122 | 0.76 | EPHX2 (0.40) | MAPK14CYP2C9MAPK11HDAC1LMNA | |
| SCHEMBL27188814 | 0.76 | EPHX2 (0.40) | MAPK14CYP2C9MAPK11HDAC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2A, GRIN2B | MAPK14 835/4885CYP2C9 4278/4885MAPK11 1039/4885 |
| US-11952344-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2A, GRIN2B | MAPK14 835/4885CYP2C9 4278/4885MAPK11 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.